Trial Profile
Pharmacokinetic study of ceftolozane/tazobactam in subjects with normal function and mild or moderate renal function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2017
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Pyelonephritis; Urinary tract infections
- Focus Pharmacokinetics
- 29 Jun 2017 New trial record
- 05 Jun 2017 Results presented at the ASM Microbe 2017